BLRX Bioline Rx Ltd
Price (delayed)
$3.1
Market cap
$13.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.01
Enterprise value
$9.32M
biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain
Highlights
Bioline Rx's gross margin has surged by 194% YoY
BLRX's net income has soared by 85% YoY and by 54% QoQ
The debt has declined by 49% since the previous quarter but it has increased by 30% year-on-year
Key stats
What are the main financial stats of BLRX
Market
Valuations
Earnings
Shares outstanding
4.47M
Market cap
$13.84M
Enterprise value
$9.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.55
Price to sales (P/S)
0.26
EV/EBIT
N/A
EV/EBITDA
2.35
EV/Sales
0.32
Revenue
$28.94M
Gross profit
$19.68M
Operating income
-$20.41M
Net income
-$9.22M
EBIT
-$102,000
EBITDA
$3.96M
Free cash flow
-$43.93M
Per share
Balance sheet
Liquidity
EPS
-$0.01
EPS diluted
-$0.01
Free cash flow per share
-$18.33
Book value per share
$5.61
Revenue per share
$12.08
TBVPS
$11.88
Total assets
$38.91M
Total liabilities
$25.45M
Debt
$15.04M
Equity
$13.46M
Working capital
$11.7M
Debt to equity
1.12
Current ratio
1.76
Quick ratio
1.53
Net debt/EBITDA
-1.14
Margins
Efficiency
Dividend
EBITDA margin
13.7%
Gross margin
68%
Net margin
-31.9%
Operating margin
-70.5%
Return on assets
-17.7%
Return on equity
-75.3%
Return on invested capital
-1.7%
Return on capital employed
-0.4%
Return on sales
-0.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLRX stock price
How has the Bioline Rx stock price performed over time
Intraday
6.16%
1 week
-2.21%
1 month
-7.46%
1 year
-90.66%
YTD
-63.79%
QTD
4.73%
Financial performance
How have Bioline Rx's revenue and profit performed over time
Revenue
$28.94M
Gross profit
$19.68M
Operating income
-$20.41M
Net income
-$9.22M
Gross margin
68%
Net margin
-31.9%
Bioline Rx's gross margin has surged by 194% YoY
The net margin has surged by 97% year-on-year and by 65% since the previous quarter
BLRX's operating margin has surged by 93% year-on-year and by 55% since the previous quarter
BLRX's net income has soared by 85% YoY and by 54% QoQ
Growth
What is Bioline Rx's growth rate over time
Valuation
What is Bioline Rx stock price valuation
P/E
N/A
P/B
0.55
P/S
0.26
EV/EBIT
N/A
EV/EBITDA
2.35
EV/Sales
0.32
BLRX's EPS has surged by 83% year-on-year
The stock's price to book (P/B) is 89% less than its last 4 quarters average of 4.6 and 84% less than its 5-year quarterly average of 3.2
The equity has soared by 58% from the previous quarter
BLRX's P/S is 94% below its last 4 quarters average of 3.7
The revenue has grown by 32% from the previous quarter
Efficiency
How efficient is Bioline Rx business performance
BLRX's return on sales has surged by 100% year-on-year and by 99% since the previous quarter
BLRX's return on assets has surged by 82% year-on-year and by 48% since the previous quarter
Bioline Rx's return on equity has surged by 73% YoY and by 54% QoQ
Dividends
What is BLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLRX.
Financial health
How did Bioline Rx financials performed over time
The company's total assets is 53% higher than its total liabilities
The company's current ratio has surged by 60% YoY and by 16% QoQ
BLRX's total liabilities is down by 50% year-on-year and by 42% since the previous quarter
The debt is 12% greater than the equity
The debt to equity has plunged by 68% from the previous quarter but it has grown by 27% YoY
The equity has soared by 58% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.